FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eldad Melamed

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Cerebrovascular Circulation

Procedures

Mesenchymal Stem Cell Transplantation

Co-author Network

Publications

TOP 3
Nirit Lev; Eldad Melamed; Yael Barhum; Haim Y Cohen; Debby Ickowicz; Neri S Pilosof; Daniel Offen
DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging.
Lior Greenbaum; Alexander Khlebtovsky; Yoav Kohn; Bernard Lerer; Mordechai Lorberboym; Eldad Melamed; Amihai Rigbi; Yael Barhum; Ruth Djaldetti
Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease.
Alexander Khlebtovsky; Eldad Melamed; Amihai Rigbi; Israel Steiner; Ilan Ziv; Alona Gad; Ruth Djaldetti
Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eldad Melamed (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nirit Lev; Eldad Melamed; Yael Barhum; Haim Y Cohen; Debby Ickowicz; Neri S Pilosof; Daniel Offen
DJ-1 protects against dopamine toxicity: implications for Parkinson's disease and aging.
The journals of gerontology. Series A, Biological sciences and medical sciences 2013;68(3):215-25.
2013: Lior Greenbaum; Alexander Khlebtovsky; Yoav Kohn; Bernard Lerer; Mordechai Lorberboym; Eldad Melamed; Amihai Rigbi; Yael Barhum; Ruth Djaldetti
Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease.
Frontiers in neuroscience 2013;7():52.
2012: Alexander Khlebtovsky; Eldad Melamed; Amihai Rigbi; Israel Steiner; Ilan Ziv; Alona Gad; Ruth Djaldetti
Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.
Journal of neural transmission (Vienna, Austria : 1996) 2012;119(11):1367-71.
2012: Yonit Fisher-Shoval; Moshe Hod; Nirit Lev; Eldad Melamed; Yael Barhum; Chen Benkler; Tali Ben-Zur; Ofer Sadan; Shlomit Yust-Katz; Daniel Offen
Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS.
Journal of molecular neuroscience : MN 2012;48(1):176-84.
2012: O Sadan; N Shemesh; M Yeshurun; Yaniv Assaf; R Barzilay; T Blumenfeld-Katzir; Y Cohen; M Dadon-Nahum; R Djaldetti; Eldad Melamed; Daniel Offen
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease.
Experimental neurology 2012;234(2):417-27.
2012: Eldad Melamed; Werner Poewe
Taking sides: is handedness involved in motor asymmetry of Parkinson's disease?
Movement disorders : official journal of the Movement Disorder Society 2012;27(2):171-3.
2012: Adi Shruster; Tali Ben-Zur; Eldad Melamed; Daniel Offen
Wnt signaling enhances neurogenesis and improves neurological function after focal ischemic injury.
PloS one 2012;7(7):e40843.
2011: Javier Ganz; Nirit Lev; Eldad Melamed; Daniel Offen
Cell replacement therapy for Parkinson's disease: how close are we to the clinic?
Expert review of neurotherapeutics 2011;11(9):1325-39.
2011: Michal Dadon-Nachum; Eldad Melamed; Ofer Sadan; Itay Srugo; Daniel Offen
Differentiated mesenchymal stem cells for sciatic nerve injury.
Stem cell reviews 2011;7(3):664-71.
2011: Rivka Inzelberg; I Liphshiz; Eldad Melamed; R Milo; J M Rabey; A Reches; M Schwartz; H Trau; J Aharon-Peretz; Samih Badarny; Micha Barchana; Oren S Cohen; Ruth Djaldetti; Cheryl Fitzer-Attas; L Gilead; Sharon Hassin-Baer; M Huberman; Nir Giladi
High prevalence of malignant melanoma in Israeli patients with Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2011;118(8):1199-207.
2011: Inna Kan; Yael Barhum; Eldad Melamed; Daniel Offen
Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice.
Stem cell reviews 2011;7(2):404-12.
2011: Michal Dadon-Nachum; Eldad Melamed; Daniel Offen
The "dying-back" phenomenon of motor neurons in ALS.
Journal of molecular neuroscience : MN 2011;43(3):470-7.
2011: Ruth Djaldetti; Mordechai Lorberboym; Yuval Karmon; Therese A Treves; Ilan Ziv; Eldad Melamed
Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: a single photon emission computed tomography imaging study.
Movement disorders : official journal of the Movement Disorder Society 2011;26(2):327-30.
2011: R Barzilay; T Ben-Zur; Z Bren; I Gil-Ad; Nirit Lev; Eldad Melamed; O Sadan; M Taler; I Tarasenko; R Uzan; A Weizman; D Offen
Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice.
Translational psychiatry 2011;1():e61.
2010: Sharon Aharoni; Teres A Traves; Eldad Melamed; Sarit Cohen; Esther Leshinsky Silver
MELAS syndrome associated with both A3243G-tRNALeu mutation and multiple mitochondrial DNA deletions.
Journal of the neurological sciences 2010;296(1-2):101-3.
2010: Mark A Hellmann; Eldad Melamed; Steinmetz Adam; Ruth Djaldetti
Unilateral lower limb rest tremor is not necessarily a presenting symptom of Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2010;25(7):924-7.
2010: Noam Shemesh; Ofer Sadan; Eldad Melamed; Daniel Offen; Yoram Cohen
Longitudinal MRI and MRSI characterization of the quinolinic acid rat model for excitotoxicity: peculiar apparent diffusion coefficients and recovery of N-acetyl aspartate levels.
NMR in biomedicine 2010;23(2):196-206.
2009: Ofer Sadan; Eldad Melamed; Daniel Offen
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.
Expert opinion on biological therapy 2009;9(12):1487-97.
2009: Ran Barzilay; Eldad Melamed; Daniel Offen
Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible.
Stem cells (Dayton, Ohio) 2009;27(10):2509-15.
2009: Ofer Sadan; Merav Bahat-Stromza; Yael Barhum; Yossef S Levy; Anat Pisnevsky; Hagit Peretz; Avihay Bar Ilan; Shlomo Bulvik; Noam Shemesh; Dana Krepel; Yoram Cohen; Eldad Melamed; Daniel Offen
Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.
Stem cells and development 2009;18(8):1179-90.
2009: C Warren Olanow; Olivier Rascol; Robert Hauser; Paul D Feigin; Joseph Jankovic; Anthony Lang; William Langston; Eldad Melamed; Werner Poewe; Fabrizio Stocchi; Eduardo Tolosa
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
The New England journal of medicine 2009;361(13):1268-78.
2009: Merav Bahat-Stroomza; Yael Barhum; Yossef S Levy; Olga Karpov; Shlomo Bulvik; Eldad Melamed; Daniel Offen
Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease.
Journal of molecular neuroscience : MN 2009;39(1-2):199-210.
2009: Ruth Djaldetti; Yair Lampl; Eldad Melamed; Therese A Treves; Ilan Ziv; Mordechai Lorberboym
Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2009;30(4):301-5.
2009: Nirit Lev; Debby Ickowicz; Yael Barhum; Eldad Melamed; Daniel Offen
DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS.
Journal of molecular neuroscience : MN 2009;38(2):94-102.
2009: Daniel Offen; Yael Barhum; Eldad Melamed; Norbert Embacher; Christoph Schindler; Gerhard Ransmayr
Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant.
Journal of molecular neuroscience : MN 2009;38(2):85-93.
2009: Ran Barzilay; Tali Ben-Zur; Shlomo Bulvik; Eldad Melamed; Daniel Offen
Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells.
Stem cells and development 2009;18(4):591-601.
2009: Ruth Djaldetti; Nirit Lev; Eldad Melamed
Lesions outside the CNS in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2009;24(6):793-800.
2009: Nir Giladi; Joseph Tal; Tali Azulay; Olivier Rascol; David J Brooks; Eldad Melamed; Wolfgang H Oertel; Werner Poewe; Fabrizio Stocchi; Eduardo Tolosa
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2009;24(5):655-61.
2009: Ofer Sadan; Noam Shemesh; Yoram Cohen; Eldad Melamed; Daniel Offen
Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases.
The Israel Medical Association journal : IMAJ 2009;11(4):201-4.
2009: Nirit Lev; Debby Ickowicz; Yael Barhum; Shaul Lev; Eldad Melamed; Daniel Offen
DJ-1 protects against dopamine toxicity.
Journal of neural transmission (Vienna, Austria : 1996) 2009;116(2):151-60.
2009: Ran Barzilay; Ofer Sadan; Eldad Melamed; Daniel Offen
Comparative characterization of bone marrow-derived mesenchymal stromal cells from four different rat strains.
Cytotherapy 2009;11(4):435-42.
2008: Shlomit Yust-Katz; Debora Tesler; Therese A Treves; Eldad Melamed; Ruth Djaldetti
Handedness as a predictor of side of onset of Parkinson's disease.
Parkinsonism & related disorders 2008;14(8):633-5.
2008: C Warren Olanow; Robert A Hauser; Joseph Jankovic; William Langston; Anthony E Lang; Werner Poewe; Eduardo Tolosa; Fabrizio Stocchi; Eldad Melamed; Eli Eyal; Olivier Rascol
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Movement disorders : official journal of the Movement Disorder Society 2008;23(15):2194-201.
2008: Ofer Sadan; Noam Shemesh; Ran Barzilay; Merav Bahat-Stromza; Eldad Melamed; Yoram Cohen; Daniel Offen
Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging.
Stem cells (Dayton, Ohio) 2008;26(10):2542-51.
2008: R Djaldetti; S Hassin-Baer; Matthew J Farrer; Carles vilarino-guell; O A Ross; V Kolianov; S Yust-Katz; T A Treves; Y Barhum; Mary Hulihan; Eldad Melamed
Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(9):1279-84.
2008: Manabu Funayama; Yuanzhe Li; Tak-Hong Tsoi; Ching-Wan Lam; Takekazu Ohi; Shogo Yazawa; Eiichiro Uyama; Ruth Djaldetti; Eldad Melamed; Hiroyo Yoshino; Yoko Imamichi; Hiroshi Takashima; Kenya Nishioka; Kenichi Sato; Hiroyuki Tomiyama; Shin-Ichiro Kubo; Yoshikuni Mizuno; Nobutaka Hattori
Familial Parkinsonism with digenic parkin and PINK1 mutations.
Movement disorders : official journal of the Movement Disorder Society 2008;23(10):1461-5.
2008: Ran Barzilay; Inna Kan; Tali Ben-Zur; Shlomo Bulvik; Eldad Melamed; Daniel Offen
Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols.
Stem cells and development 2008;17(3):547-54.
2008: Nirit Lev; Debby Ickowicz; Eldad Melamed; Daniel Offen
Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection.
Neurotoxicology 2008;29(3):397-405.
2008: Shlomit Yust-Katz; Sonia Sthneer; Eldad Melamed; Ruth Djaldetti
Long-term Parkinson's disease--time for optimism.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2008;62(4):233-5.
2008: Mark A Hellmann; Tilda Sabach; Eldad Melamed; Ruth Djaldetti
Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2008;62(4):250-2.
2008: Yossef S Levy; M Bahat-Stroomza; R Barzilay; A Burshtein; Shlomo Bulvik; Yael Barhum; Hana Panet; Eldad Melamed; Daniel Offen
Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease.
Cytotherapy 2008;10(4):340-52.
2008: R Djaldetti; B I Nageris; M Lorberboym; T A Treves; Eldad Melamed; E Yaniv
[(123)I]-FP-CIT SPECT and olfaction test in patients with combined postural and rest tremor.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(3):469-72.
2007: Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Mordechai Lorberboym
123I-FP-CIT SPECT imaging of dopamine transporters in patients with recurrent sudden falls: are such falls a distinct entity?
Journal of nuclear medicine technology 2007;35(4):232-6.
2007: Eldad Melamed; Ilan Ziv; Ruth Djaldetti
Management of motor complications in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2007;22 Suppl 17():S379-84.
2007: Ruth Djaldetti; Shlomit Yust-Katz; Vadim Kolianov; Eldad Melamed; Ron Dabby
The effect of duloxetine on primary pain symptoms in Parkinson disease.
Clinical neuropharmacology 2007;30(4):201-5.
2007: Inna Kan; Tali Ben-Zur; Yael Barhum; Yossef S Levy; Alex Burstein; Tirza Charlow; Shlomo Bulvik; Eldad Melamed; Daniel Offen
Dopaminergic differentiation of human mesenchymal stem cells--utilization of bioassay for tyrosine hydroxylase expression.
Neuroscience letters 2007;419(1):28-33.
2007: Alon Abraham; Cogan Elena; Eldad Melamed; Ruth Djaldetti
Successful treatment of truncal myoclonus.
Movement disorders : official journal of the Movement Disorder Society 2007;22(7):1055-6.
2007: Ayelet Reshef; Anat Shirvan; Hagit Grimberg; Galit Levin; Avi Cohen; Adi Mayk; Dvora Kidron; Ruth Djaldetti; Eldad Melamed; Ilan Ziv
Novel molecular imaging of cell death in experimental cerebral stroke.
Brain research 2007;1144():156-64.
2007: Irene Litvan; Marie-Francoise Chesselet; Thomas Gasser; Donato A Di Monte; Davis Parker; Theo Hagg; John Hardy; Peter Jenner; Richard H Myers; Donald L Price; Mark Hallett; William J Langston; Anthony E Lang; Glenda Halliday; Walter Rocca; Charles Duyckaerts; dennis dickson; Yoav Ben-Shlomo; Christopher G Goetz; Eldad Melamed
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II.
Journal of neuropathology and experimental neurology 2007;66(5):329-36.
2007: Irene Litvan; Glenda Halliday; Mark Hallett; Christopher G Goetz; Walter Rocca; Charles Duyckaerts; Yoav Ben-Shlomo; dennis dickson; Anthony E Lang; Marie-Francoise Chesselet; William J Langston; Donato A Di Monte; Thomas Gasser; Theo Hagg; John Hardy; Peter Jenner; Eldad Melamed; Richard H Myers; Davis Parker; Donald L Price
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I.
Journal of neuropathology and experimental neurology 2007;66(4):251-7.
2007: Inna Kan; Eldad Melamed; Daniel Offen; Pnina Green
Docosahexaenoic acid and arachidonic acid are fundamental supplements for the induction of neuronal differentiation.
Journal of lipid research 2007;48(3):513-7.
2007: Jonathan F Grunfeld; Yael Barhum; Netta Blondheim; Jose Martin Rabey; Eldad Melamed; Daniel Offen
Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model.
Experimental neurology 2007;204(1):260-3.
2007: Nirit Lev; Eldad Melamed; Daniel Offen
Toxic causes of parkinsonism.
Handbook of clinical neurology 2007;84():385-98.
2007: William Koller; Eldad Melamed
Preface.
Handbook of clinical neurology 2007;84():IX.
2007: Ruth Djaldetti; Eldad Melamed
Sensory symptoms in Parkinson's disease.
Handbook of clinical neurology 2007;83():377-84.
2007: William Koller; Eldad Melamed
Preface.
Handbook of clinical neurology 2007;83():IX.
2007: Daniel Offen; Yael Barhum; Yossef S Levy; A Burshtein; Hana Panet; T Cherlow; Eldad Melamed
Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease.
Journal of neural transmission. Supplementum 2007;(72):133-43.
2007: Inna Kan; Eldad Melamed; Daniel Offen
Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases.
Handbook of experimental pharmacology 2007;(180):219-42.
2006: Ruth Djaldetti; Mordechai Lorberboym; Eldad Melamed
Primary postural instability: a cause of recurrent sudden falls in the elderly.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2006;27(6):412-6.
2006: Eldad Melamed; Ruth Djaldetti
Camptocormia in Parkinson's disease.
Journal of neurology 2006;253 Suppl 7():VII14-16.
2006: R Djaldetti; Eldad Melamed
Camptocormia in Parkinson's disease: new insights.
Journal of neurology, neurosurgery, and psychiatry 2006;77(11):1205.
2006: Nirit Lev; Debby Ickowicz; Yael Barhum; Netta Blondheim; Eldad Melamed; Daniel Offen
Experimental encephalomyelitis induces changes in DJ-1: implications for oxidative stress in multiple sclerosis.
Antioxidants & redox signaling 2006;8(11-12):1987-95.
2006: Mark A Hellmann; Ruth Djaldetti; Zvi Israel; Eldad Melamed
Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(11):2008-10.
2006: Ruth Djaldetti; Ilan Ziv; Eldad Melamed
The mystery of motor asymmetry in Parkinson's disease.
Lancet neurology 2006;5(9):796-802.
2006: Ron Dabby; Ruth Djaldetti; Mark Shahmurov; Therese A Treves; B Gabai; Eldad Melamed; Menachem Sadeh; Ilana Avinoach
Skin biopsy for assessment of autonomic denervation in Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(9):1169-76.
2006: Daniel Oved; Ilan Ziv; Therese A Treves; Diana Paleacu; Eldad Melamed; Ruth Djaldetti
Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(8):1257-61.
2006: Hiroyuki Tomiyama; Yuanzhe Li; Manabu Funayama; Kazuko Hasegawa; Hiroyo Yoshino; Shin-Ichiro Kubo; Kenichi Sato; Tatsuya Hattori; Chin-Song Lu; Rivka Inzelberg; Ruth Djaldetti; Eldad Melamed; Rim Amouri; Neziha Gouider-Khouja; Faycal Hentati; Yasuko Hatano; Mei Wang; Yoko Imamichi; Koichi Mizoguchi; Hiroaki Miyajima; Fumiya Obata; Tatsushi Toda; Matthew J Farrer; Yoshikuni Mizuno; Nobutaka Hattori
Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
Movement disorders : official journal of the Movement Disorder Society 2006;21(8):1102-8.
2006: Nirit Lev; Eldad Melamed; Daniel Offen
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Neuroscience letters 2006;399(1-2):27-32.
2006: Netta Blondheim; Yossef S Levy; Tali Ben-Zur; Alex Burshtein; Tirza Cherlow; Inna Kan; Ran Barzilai; Merav Bahat-Stromza; Yael Barhum; Shlomo Bulvik; Eldad Melamed; Daniel Offen
Human mesenchymal stem cells express neural genes, suggesting a neural predisposition.
Stem cells and development 2006;15(2):141-64.
2006: Mordechai Lorberboym; Therese A Treves; Eldad Melamed; Yair Lampl; Mark A Hellmann; Ruth Djaldetti
[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2006;21(4):510-4.
2006: Mark A Hellmann; Hana Panet; Yael Barhum; Eldad Melamed; Daniel Offen
Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents.
Neuroscience letters 2006;395(2):124-8.
2006: Nirit Lev; Dusan Roncevic; Dusan Roncevich; Debby Ickowicz; Eldad Melamed; Daniel Offen
Role of DJ-1 in Parkinson's disease.
Journal of molecular neuroscience : MN 2006;29(3):215-25.
2006: Yossi Gilgun-Sherki; Eldad Melamed; Daniel Offen
Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.
Current pharmaceutical design 2006;12(27):3509-19.
2006: Ran Barzilay; Yossef S Levy; Eldad Melamed; Daniel Offen
Adult stem cells for neuronal repair.
The Israel Medical Association journal : IMAJ 2006;8(1):61-6.
2005: Ofer Sadan; Merav Bahat-Stromza; Yossi Gilgun-Sherki; Daphne Atlas; Eldad Melamed; Daniel Offen
A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia.
Clinical neuropharmacology 2005;28(6):285-8.
2005: Olivier Rascol; David J Brooks; Eldad Melamed; Wolfgang H Oertel; Werner Poewe; Fabrizio Stocchi; E Tolosa
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Lancet 2005;365(9463):947-54.
2005: Merav Bahat-Stroomza; Yossi Gilgun-Sherki; Daniel Offen; Hana Panet; Ann Saada (Reisch); Nili Krool-Galron; Aari Barzilai; Daphne Atlas; Eldad Melamed
A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease.
The European journal of neuroscience 2005;21(3):637-46.
2005: Inna Kan; Eldad Melamed; Daniel Offen
Integral therapeutic potential of bone marrow mesenchymal stem cells.
Current drug targets 2005;6(1):31-41.
2005: Yossi Gilgun-Sherki; Yael Barhum; Daphne Atlas; Eldad Melamed; Daniel Offen
Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant.
Journal of molecular neuroscience : MN 2005;27(1):125-35.
2005: Yossef S Levy; Yossi Gilgun-Sherki; Eldad Melamed; Daniel Offen
Therapeutic potential of neurotrophic factors in neurodegenerative diseases.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2005;19(2):97-127.
2004: Ruth Djaldetti; Mark A Hellmann; Eldad Melamed
Bent knees and tiptoeing: late manifestations of end-stage Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2004;19(11):1325-8.
2004: Mordechai Lorberboym; Ruth Djaldetti; Eldad Melamed; Menachem Sadeh; Yair Lampl
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(10):1688-93.
2004: C Warren Olanow; Yves Agid; Yoshikuni Mizuno; Alberto Albanese; Ubaldo Bonuccelli; U Bonucelli; Philippe Damier; Justo De Yebenes; Oscar S Gershanik; Mark Guttman; Francisco Grandas; Mark Hallett; Oleh Hornykiewicz; Peter Jenner; Regina Katzenschlager; William J Langston; Peter LeWitt; Eldad Melamed; M A Mena; Patrick P Michel; Catherine Mytilineou; Jose A Obeso; Werner Poewe; Niall Quinn; Rita Raisman-Vozari; Ali H Rajput; Olivier Rascol; Cristina Sampaio; Fabrizio Stocchi
Levodopa in the treatment of Parkinson's disease: current controversies.
Movement disorders : official journal of the Movement Disorder Society 2004;19(9):997-1005.
2004: Ruth Djaldetti; A Shifrin; Zeev Rogowski; E Sprecher; Eldad Melamed; David Yarnitsky
Quantitative measurement of pain sensation in patients with Parkinson disease.
Neurology 2004;62(12):2171-5.
2004: Daniel Offen; Yossi Gilgun-Sherki; Yael Barhum; Moran Benhar; Leonid Grinberg; Reuven Reich; Eldad Melamed; Daphne Atlas
A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis.
Journal of neurochemistry 2004;89(5):1241-51.
2004: Nirit Lev; Yael Barhum; Eldad Melamed; Daniel Offen
Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice.
Neuroscience letters 2004;359(3):139-42.
2004: Yossi Gilgun-Sherki; Eldad Melamed; Daniel Offen
The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy.
Journal of neurology 2004;251(3):261-8.
2004: Hanock Elkon; Eldad Melamed; Daniel Offen
Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.
Journal of molecular neuroscience : MN 2004;24(3):387-400.
2004: Yossef S Levy; Merav Stroomza; Eldad Melamed; Daniel Offen
Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.
Journal of molecular neuroscience : MN 2004;24(3):353-86.
2004: Yossi Gilgun-Sherki; Ruth Djaldetti; Eldad Melamed; Daniel Offen
Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.
The pharmacogenomics journal 2004;4(5):291-306.
2004: Jonathan Y Streifler; Diana Israel; Eldad Melamed
The hyperperfusion syndrome: an under-recognized complication of carotid endarterectomy.
The Israel Medical Association journal : IMAJ 2004;6(1):54-6.
2003: Yossi Gilgun-Sherki; Hana Panet; Eldad Melamed; Daniel Offen
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.
Brain research 2003;989(2):196-204.
2003: Ruth Djaldetti; Nir Giladi; Sharon Hassin-Baer; Herzel Shabtai; Eldad Melamed
Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.
Clinical neuropharmacology 2003;26(6):322-6.
2003: Ruth Djaldetti; Nirit Lev; Eldad Melamed
Neuroprotection in progressive brain disorders.
The Israel Medical Association journal : IMAJ 2003;5(8):576-80.
2003: Yossi Gilgun-Sherki; Eldad Melamed; Urij Rampampam; Daniel Offen
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Pharmacology & toxicology 2003;93(2):66-70.
2003: Doron Merims; Ruth Djaldetti; Eldad Melamed
Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations.
Clinical neuropharmacology 2003;26(4):196-8.
2003: Yossi Gilgun-Sherki; Eldad Melamed; Ilan Ziv; Daniel Offen
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Pharmacology & toxicology 2003;93(1):54-6.
2003: Nirit Lev; Eldad Melamed; Daniel Offen
Apoptosis and Parkinson's disease.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(2):245-50.
2003: Ari Barzilai; Eldad Melamed
Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease.
Trends in molecular medicine 2003;9(3):126-32.
2003: Yossef S Levy; Doron Merims; Hana Panet; Yael Barhum; Eldad Melamed; Daniel Offen
Induction of neuron-specific enolase promoter and neuronal markers in differentiated mouse bone marrow stromal cells.
Journal of molecular neuroscience : MN 2003;21(2):121-32.
2003: Yossi Gilgun-Sherki; Eldad Melamed; Daniel Offen
Antioxidant treatment in Alzheimer's disease: current state.
Journal of molecular neuroscience : MN 2003;21(1):1-11.
2003: Ruth Djaldetti; Therese A Treves; Doron Merims; Hava Sroka; Eldad Melamed
Effect of late initiation of levodopa treatment in patients with long-standing Parkinson's disease.
Clinical neuropharmacology 2003;26(1):24-7.
2003: Ari Barzilai; Dorah Daily; Rina Zilkha-Falb; Ilan Ziv; Daniel Offen; Eldad Melamed; Anat Shirvan
The molecular mechanisms of dopamine toxicity.
Advances in neurology 2003;91():73-82.
2002: Anat Shirvan; Michal Kimron; Vered Holdengreber; Ilan Ziv; Yehuda Ben-Shaul; Shlomo Melamed; Eldad Melamed; Ari Barzilai; Arieh S Solomon
Anti-semaphorin 3A antibodies rescue retinal ganglion cells from cell death following optic nerve axotomy.
The Journal of biological chemistry 2002;277(51):49799-807.
2002: Ruth Djaldetti; Eldad Melamed
New drugs in the future treatment of Parkinson's disease.
Journal of neurology 2002;249 Suppl 2():II30-5.
2002: Nirit Lev; Eldad Melamed
[Neurological complications in Down's Syndrome].
Harefuah 2002;141(9):820-3, 857.
2002: Mark A Hellmann; Eldad Melamed
Focal dystonia as the presenting sign in Creutzfeldt-Jakob disease.
Movement disorders : official journal of the Movement Disorder Society 2002;17(5):1097-8.
2002: Eldad Melamed; D Robinson; Nahum Halperin; N Wallach; Ofer Keren; Zeev Groswasser
Brain injury-related heterotopic bone formation: treatment strategy and results.
American journal of physical medicine & rehabilitation / Association of Academic Physiatrists 2002;81(9):670-4.
2002: Hanock Elkon; Jermy Don; Eldad Melamed; Ilan Ziv; Anat Shirvan; Daniel Offen
Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase.
Journal of molecular neuroscience : MN 2002;18(3):229-38.
2002: Yossi Gilgun-Sherki; Ziv Rosenbaum; Eldad Melamed; Daniel Offen
Antioxidant therapy in acute central nervous system injury: current state.
Pharmacological reviews 2002;54(2):271-84.
2002: Ruth Djaldetti; Ilan Ziv; Eldad Melamed
The effect of deprenyl washout in patients with long-standing Parkinson's disease.
Journal of neural transmission (Vienna, Austria : 1996) 2002;109(5-6):797-803.
2002: Ruth Djaldetti; Rivka Inzelberg; Nir Giladi; Amos D Korczyn; Yehudit Peretz-Aharon; Martin J Rabey; Yuval Herishano; Silvia Honigman; Samih Badarny; Eldad Melamed
Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2002;17(2):297-302.
2002: Nirit Lev; Shalom Michowiz; Edna Inbar; Claire I Coire; Silvio Pitlik; Eldad Melamed
Neurocysticercosis.
The Israel Medical Association journal : IMAJ 2002;4(1):65-6.
2001: Daniel Offen; Biana Shtaif; D Hadad; Abraham Weizman; Eldad Melamed; Irit Gil-Ad
Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease.
Neuroscience letters 2001;316(3):129-32.
2001: Hanock Elkon; Eldad Melamed; Daniel Offen
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease.
Cellular and molecular neurobiology 2001;21(6):771-81.
2001: Ruth Djaldetti; Eldad Melamed; N Gadoth
Abnormal skin wrinkling in the less affected side in hemiparkinsonism-a possible test for sympathetic dysfunction in Parkinson's disease.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2001;55(8):475-8.
2001: Nirit Lev; Shimon Maimon; Z Harry Rappaport; Eldad Melamed
Spinal dural arteriovenous fistulae--a diagnostic challenge.
The Israel Medical Association journal : IMAJ 2001;3(7):492-6.
2001: Dorah Daily; A Vlamis-Gardikas; Daniel Offen; Leonid Mittelman; Eldad Melamed; A Holmgren; Ari Barzilai
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways.
The Journal of biological chemistry 2001;276(24):21618-26.
2001: Ari Barzilai; Eldad Melamed; Anat Shirvan
Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?
Cellular and molecular neurobiology 2001;21(3):215-35.
2001: Nirit Lev; Eldad Melamed
Heredity in Parkinson's disease: new findings.
The Israel Medical Association journal : IMAJ 2001;3(6):435-8.
2001: Yossi Gilgun-Sherki; Eldad Melamed; Daniel Offen
Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier.
Neuropharmacology 2001;40(8):959-75.
2001: Ruth Djaldetti; Eldad Melamed
New therapies for Parkinson's disease.
Journal of neurology 2001;248(5):357-62.
2001: Hana Panet; Ari Barzilai; Dorah Daily; Eldad Melamed; Daniel Offen
Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells.
Journal of neurochemistry 2001;77(2):391-8.
2001: Ruth Djaldetti; V Rosmarin; Ilan Ziv; Eldad Melamed
The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.
Clinical neuropharmacology 2001;24(2):95-8.
2001: Alberto Albanese; Ubaldo Bonuccelli; C Brefel; K Ray Chaudhuri; C Colosimo; T Eichhorn; Eldad Melamed; Pierre Pollak; T Van Laar; M Zappia
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2001;16(2):197-201.
2001: Dorah Daily; A Vlamis-Gardikas; Daniel Offen; Leonid Mittelman; Eldad Melamed; A Holmgren; Ari Barzilai
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1.
The Journal of biological chemistry 2001;276(2):1335-44.
2001: Ilan Ziv; Anat Shirvan; Daniel Offen; Ari Barzilai; Eldad Melamed
Molecular biology of dopamine-induced apoptosis : possible implications for Parkinson's disease.
Methods in molecular medicine 2001;62():73-87.
2001: Doron Merims; Ilan Ziv; Y Sherki; Ruth Djaldetti; Eldad Melamed
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Neurologia i neurochirurgia polska 2001;35 Suppl 3():65-8.
2001: Daniel Offen; Hana Panet; R Galili-Mosberg; Eldad Melamed
Catechol-O-methyltransferase decreases levodopa toxicity in vitro.
Clinical neuropharmacology 2001;24(1):27-30.
2000: Daniel Offen; Joel F Kaye; O Bernard; Doron Merims; C I Coire; Hana Panet; Eldad Melamed; Avraham Ben-Nun
Mice overexpressing Bcl-2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE).
Journal of molecular neuroscience : MN 2000;15(3):167-76.
2000: Rina Zilkha-Falb; Ari Barzilai; R Djaldeti; Ilan Ziv; Eldad Melamed; Anat Shirvan
Involvement of T-complex protein-1delta in dopamine triggered apoptosis in chick embryo sympathetic neurons.
The Journal of biological chemistry 2000;275(46):36380-7.
2000: Anat Shirvan; R Shina; Ilan Ziv; Eldad Melamed; Ari Barzilai
Induction of neuronal apoptosis by Semaphorin3A-derived peptide.
Brain research. Molecular brain research 2000;83(1-2):81-93.
2000: Jose Martin Rabey; I Sagi; M Huberman; Eldad Melamed; Amos D Korczyn; Nir Giladi; Rivka Inzelberg; Ruth Djaldetti; Colin Klein; G Berecz
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Clinical neuropharmacology 2000;23(6):324-30.
2000: Eldad Melamed; D Keren; D Robinson; N Halperin; Z Mrosswasser
[Periarticular new bone formation following traumatic brain injury].
Harefuah 2000;139(9-10):368-71.
2000: Abraham Rudnick; Y Ezra; Eldad Melamed
Breaking bad news and personality assessment.
Patient education and counseling 2000;41(2):157-60.
2000: Doron Merims; R Galili-Mosberg; Eldad Melamed
Is there addiction to levodopa in patients with Parkinson's disease?
Movement disorders : official journal of the Movement Disorder Society 2000;15(5):1014-6.
2000: Nir Giladi; Eldad Melamed
The role of functional neurosurgery in Parkinson's disease.
The Israel Medical Association journal : IMAJ 2000;2(6):455-61.
2000: Eldad Melamed; Daniel Offen; Anat Shirvan; Ilan Ziv
Levodopa--an exotoxin or a therapeutic drug?
Journal of neurology 2000;247 Suppl 2():II135-9.
2000: N Lev; Eldad Melamed
[Sensory symptoms and pain in Parkinson disease].
Harefuah 2000;138(4):324-6.
2000: Ayala Hochman; Huiyun Liang; Daniel Offen; Eldad Melamed; H Sternin
Developmental changes in antioxidant enzymes and oxidative damage in kidneys, liver and brain of bcl-2 knockout mice.
Cellular and molecular biology (Noisy-le-Grand, France) 2000;46(1):41-52.
2000: Daniel Offen; Y Sherki; Eldad Melamed; Mati Fridkin; Douglas E Brenneman; Illana Gozes
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Brain research 2000;854(1-2):257-62.
2000: R Galili; Irit Gil-Ad; A Weizman; Eldad Melamed; Daniel Offen
Haloperidol-induced neurotoxicity--possible implications for tardive dyskinesia.
Journal of neural transmission (Vienna, Austria : 1996) 2000;107(4):479-90.
2000: Ari Barzilai; Rina Zilkha-Falb; Dorah Daily; Naftali Stern; Daniel Offen; Ilan Ziv; Eldad Melamed; Anat Shirvan
The molecular mechanism of dopamine-induced apoptosis: identification and characterization of genes that mediate dopamine toxicity.
Journal of neural transmission. Supplementum 2000;(60):59-76.
2000: Daniel Offen; Hanock Elkon; Eldad Melamed
Apoptosis as a general cell death pathway in neurodegenerative diseases.
Journal of neural transmission. Supplementum 2000;(58):153-66.
1999: Nirit Lev; Shimon Maimon; Eldad Melamed; E Inbar; Z Harry Rappaport
[Spinal dural arteriovenous fistula].
Harefuah 1999;137(10):471-4.
1999: J Zoldan; Doron Merims; A Kuritzky; Ilan Ziv; Eldad Melamed
[Apomorphine for treatment of "off-periods" in Parkinson's disease].
Harefuah 1999;137(10):444-6, 512, 511.
1999: Yves Agid; E Ahlskog; A Albanese; Donald B Calne; Thomas N Chase; J De Yebenes; Stewart A Factor; Stanley Fahn; Oscar S Gershanik; Christopher G Goetz; William Koller; M Kurth; Anthony E Lang; Andrew J Lees; Peter LeWitt; D Marsden; Eldad Melamed; Patrick P Michel; Yoshikuni Mizuno; Jose A Obeso; Wolfgang H Oertel; W Olanow; Werner Poewe; Pierre Pollak; Eduardo Tolosa
Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Movement disorders : official journal of the Movement Disorder Society 1999;14(6):911-3.
1999: Anat Shirvan; Ilan Ziv; G Fleminger; R Shina; Z He; I Brudo; Eldad Melamed; Ari Barzilai
Semaphorins as mediators of neuronal apoptosis.
Journal of neurochemistry 1999;73(3):961-71.
1999: Doron Merims; Ilan Ziv; Ruth Djaldetti; Eldad Melamed
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
Lancet 1999;353(9166):1764-5.
1999: Ruth Djaldetti; R Mosberg-Galili; Hava Sroka; Doron Merims; Eldad Melamed
Camptocormia (bent spine) in patients with Parkinson's disease--characterization and possible pathogenesis of an unusual phenomenon.
Movement disorders : official journal of the Movement Disorder Society 1999;14(3):443-7.
1999: Dorah Daily; Ari Barzilai; Daniel Offen; A Kamsler; Eldad Melamed; Ilan Ziv
The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53.
Cellular and molecular neurobiology 1999;19(2):261-76.
1999: Ilan Ziv; M Avraham; Ron Dabby; J Zoldan; Ruth Djaldetti; Eldad Melamed
Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment.
Acta neurologica Scandinavica 1999;99(2):106-11.
1999: Daniel Offen; Svetlana Gorodin; Eldad Melamed; J Hanania; Z Malik
Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease.
Neuroscience letters 1999;260(2):101-4.
1999: Eldad Melamed; C Warren Olanow; John G Nutt; Anthony E Lang
Dyskinesias assessment workshop: reports from the working groups.
Movement disorders : official journal of the Movement Disorder Society 1999;14 Suppl 1():69-73.
1999: Daniel Offen; Ayala Hochman; Svetlana Gorodin; Ilan Ziv; Anat Shirvan; Ari Barzilai; Eldad Melamed
Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis.
Advances in neurology 1999;80():265-9.
1999: Eldad Melamed; J Zoldan; R Galili-Mosberg; Ilan Ziv; Ruth Djaldetti
Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
Journal of neural transmission. Supplementum 1999;56():173-83.
1999: Eldad Melamed; G Friedberg; J Zoldan
Psychosis: impact on the patient and family.
Neurology 1999;52(7 Suppl 3):S14-6.
1999: Nir Giladi; Eldad Melamed
Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism.
Movement disorders : official journal of the Movement Disorder Society 1999;14(1):158-9.
1998: Ilan Ziv; M Avraham; Y Michaelov; Ruth Djaldetti; R Dressler; J Zoldan; Eldad Melamed
Enhanced fatigue during motor performance in patients with Parkinson's disease.
Neurology 1998;51(6):1583-6.
1998: Ilan Ziv; Ruth Djaldetti; Y Zoldan; M Avraham; Eldad Melamed
Diagnosis of "non-organic" limb paresis by a novel objective motor assessment: the quantitative Hoover's test.
Journal of neurology 1998;245(12):797-802.
1998: I Ziv; Eldad Melamed
Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity?
Movement disorders : official journal of the Movement Disorder Society 1998;13(6):865-70.
1998: Daniel Offen; S Halevi; D Orion; R Mosberg; H Stern-Goldberg; Eldad Melamed; Daphne Atlas
Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels.
Neurology 1998;51(4):1100-3.
1998: G Friedberg; J Zoldan; A Weizman; Eldad Melamed
Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease.
Clinical neuropharmacology 1998;21(5):280-4.
1998: Eldad Melamed; Daniel Offen; Anat Shirvan; Ruth Djaldetti; Ari Barzilai; Ilan Ziv
Levodopa toxicity and apoptosis.
Annals of neurology 1998;44(3 Suppl 1):S149-54.
1998: Ruth Djaldetti; Eldad Melamed
Management of response fluctuations: practical guidelines.
Neurology 1998;51(2 Suppl 2):S36-40.
1998: Ayala Hochman; H Sternin; Svetlana Gorodin; S Korsmeyer; Ilan Ziv; Eldad Melamed; Daniel Offen
Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice.
Journal of neurochemistry 1998;71(2):741-8.
1998: Daniel Offen; Philip M Beart; Nam Sang Cheung; CJ Pascoe; Ayala Hochman; Svetlana Gorodin; Eldad Melamed; R Bernard; O Bernard
Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(10):5789-94.
1998: Ruth Djaldetti; Ilan Ziv; Eldad Melamed
Extreme anticipation in young-onset Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13(3):599-600.
1998: Anat Shirvan; Ilan Ziv; Rina Zilkha-Falb; T Machlyn; Ari Barzilai; Eldad Melamed
Expression of cell cycle-related genes during neuronal apoptosis: is there a distinct pattern?
Neurochemical research 1998;23(5):767-77.
1997: Anat Shirvan; Ilan Ziv; T Machlin; Rina Zilkha-Falb; Eldad Melamed; Ari Barzilai
Two waves of cyclin B and proliferating cell nuclear antigen expression during dopamine-triggered neuronal apoptosis.
Journal of neurochemistry 1997;69(2):539-49.
1997: Daniel Offen; Ilan Ziv; Ari Barzilai; Svetlana Gorodin; E Glater; Ayala Hochman; Eldad Melamed
Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease.
Neurochemistry international 1997;31(2):207-16.
1997: Daniel Offen; Ilan Ziv; Hana Panet; L Wasserman; R Stein; Eldad Melamed; Ari Barzilai
Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2.
Cellular and molecular neurobiology 1997;17(3):289-304.
1997: Rina Zilkha-Falb; Ilan Ziv; N Nardi; Daniel Offen; Eldad Melamed; Ari Barzilai
Monoamine-induced apoptotic neuronal cell death.
Cellular and molecular neurobiology 1997;17(1):101-18.
1997: Ilan Ziv; Daniel Offen; R Haviv; R Stein; Hana Panet; Rina Zilkha-Falb; Anat Shirvan; Ari Barzilai; Eldad Melamed
The proto-oncogene Bcl-2 inhibits cellular toxicity of dopamine: possible implications for Parkinson's disease.
Apoptosis : an international journal on programmed cell death 1997;2(2):149-55.
1997: Ilan Ziv; Daniel Offen; Ari Barzilai; R Haviv; R Stein; Rina Zilkha-Falb; Anat Shirvan; Eldad Melamed
Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?
Journal of neural transmission. Supplementum 1997;49():195-202.
1997: Ilan Ziv; Ari Barzilai; Daniel Offen; N Nardi; Eldad Melamed
Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process?
Journal of neural transmission. Supplementum 1997;49():69-76.
1997: Anat Shirvan; Ilan Ziv; Ari Barzilai; R Djaldeti; R Zilkh-Falb; T Michlin; Eldad Melamed
Induction of mitosis-related genes during dopamine-triggered apoptosis in sympathetic neurons.
Journal of neural transmission. Supplementum 1997;50():67-78.
1997: Ilan Ziv; Rina Zilkha-Falb; Daniel Offen; Anat Shirvan; Ari Barzilai; Eldad Melamed
Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
Movement disorders : official journal of the Movement Disorder Society 1997;12(1):17-23.
1996: Ruth Djaldetti; Ilan Ziv; Eldad Melamed
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
Israel journal of medical sciences 1996;32(12):1224-7.
1996: R Djaldetti; Eldad Melamed
Posttraumatic-delayed cerebellar syndrome.
Archives of neurology 1996;53(12):1214-5.
1996: Daniel Offen; Ilan Ziv; H Sternin; Eldad Melamed; Ayala Hochman
Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease.
Experimental neurology 1996;141(1):32-9.
1996: Ruth Djaldetti; J Baron; Ilan Ziv; Eldad Melamed
Gastric emptying in Parkinson's disease: patients with and without response fluctuations.
Neurology 1996;46(4):1051-4.
1996: Ruth Djaldetti; Ilan Ziv; Anat Achiron; Eldad Melamed
Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment.
Neurology 1996;46(3):632-5.
1996: Ruth Djaldetti; Eldad Melamed
Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.
Annals of neurology 1996;39(3):400-4.
1996: Ruth Djaldetti; D Atlas; Eldad Melamed
Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease.
Clinical neuropharmacology 1996;19(1):65-71.
1996: Eldad Melamed; J Zoldan; G Friedberg; Ilan Ziv; A Weizmann
Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
Advances in neurology 1996;69():545-50.
1996: J Zoldan; G Friedberg; A Weizman; Eldad Melamed
Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.
Advances in neurology 1996;69():541-4.
1996: Ilan Ziv; Ari Barzilai; Daniel Offen; R Stein; Anat Achiron; Eldad Melamed
Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease?
Advances in neurology 1996;69():229-33.
1995: Daniel Offen; Ilan Ziv; Svetlana Gorodin; Ari Barzilai; Z Malik; Eldad Melamed
Dopamine-induced programmed cell death in mouse thymocytes.
Biochimica et biophysica acta 1995;1268(2):171-7.
1995: Ruth Djaldetti; A Achiron; I Ziv; Meir Djaldetti; Eldad Melamed; P Fishman
IL-3-LA production by mononuclear cells of patients with multiple sclerosis: effect of treatment with intravenous immunoglobulins.
Immunological investigations 1995;24(5):765-73.
1995: J Zoldan; G Friedberg; M Livneh; Eldad Melamed
Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist.
Neurology 1995;45(7):1305-8.
1995: V R Nerurkar; Anat Achiron; K J Song; R R Melland; Orit Pinhas-Hamiel; Eldad Melamed; B Shohat; R Yanagihara
Human T-cell lymphotropic virus type I in Iranian-born Mashhadi Jews: genetic and phylogenetic evidence for common source of infection.
Journal of medical virology 1995;45(4):361-6.
1995: Eldad Melamed
Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
Journal of neural transmission. Supplementum 1995;45():57-60.
1995: Ruth Djaldetti; M Koren; Ilan Ziv; A Achiron; Eldad Melamed
Effect of cisapride on response fluctuations in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1995;10(1):81-4.
1995: Anat Achiron; I R Cohen; O Lider; Eldad Melamed
Intravenous immunoglobulin treatment in multiple sclerosis.
Israel journal of medical sciences 1995;31(1):7-9.
1994: Anat Achiron; Ronit Gilad; R Margalit; uri gabbay; Ida Sarova-Pinhas; I R Cohen; Eldad Melamed; O Lider; S Noy; I Ziv
Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action.
Journal of neurology, neurosurgery, and psychiatry 1994;57 Suppl():57-61.
1994: I Ziv; A Achiron; Ruth Djaldetti; M Abraham; Eldad Melamed
Can nimodipine affect progression of motor neuron disease? A double-blind pilot study.
Clinical neuropharmacology 1994;17(5):423-8.
1994: R Djaldetti; A Achiron; I Ziv; Eldad Melamed
First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy.
Movement disorders : official journal of the Movement Disorder Society 1994;9(5):582-3.
1994: H Goldberg-Stern; R D'jaldetti; Eldad Melamed; N Gadoth
Machado-Joseph (Azorean) disease in a Yemenite Jewish family in Israel.
Neurology 1994;44(7):1298-301.
1994: H Goldberg-Stern; Eldad Melamed; N Gadoth
Abnormal evoked potentials in Miller-Fisher syndrome: further evidence of combined peripheral and central demyelination.
Journal of neurology, neurosurgery, and psychiatry 1994;57(4):506.
1994: Ilan Ziv; Eldad Melamed; N Nardi; D Luria; Anat Achiron; Daniel Offen; Ari Barzilai
Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease.
Neuroscience letters 1994;170(1):136-40.
1994: Caroline M Tanner; Eldad Melamed; Andrew J Lees
Managing motor fluctuations, dyskinesias, and other adverse effects in Parkinson's disease.
Neurology 1994;44(3 Suppl 1):S12-6.
1993: Anat Achiron; Orit Pinhas-Hamiel; L Doll; Ruth Djaldetti; A Chen; Ilan Ziv; A Avni; G Frankel; Eldad Melamed; B Shohat
Spastic paraparesis associated with human T-lymphotropic virus type I: a clinical, serological, and genomic study in Iranian-born Mashhadi Jews.
Annals of neurology 1993;34(5):670-5.
1993: A Achiron; I Ziv; M Goren; H Goldberg; Y Zoldan; H Sroka; Eldad Melamed
Primary progressive freezing gait.
Movement disorders : official journal of the Movement Disorder Society 1993;8(3):293-7.
1993: J Zoldan; G Friedberg; H Goldberg-Stern; Eldad Melamed
Ondansetron for hallucinosis in advanced Parkinson's disease.
Lancet 1993;341(8844):562-3.
1993: I Ziv; A Achiron; Ruth Djaldetti; R Dressler; Eldad Melamed
Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment.
Clinical neuropharmacology 1993;16(1):54-60.
1993: H Goldberg-Stern; D Atlas; L Schwartz; A Achiron; I Ziv; Ruth Djaldetti; Y Zoldan; Eldad Melamed
Detection and measurement of an endogenous clonidine-displacing substance in human cerebrospinal fluid.
Brain research 1993;601(1-2):325-8.
1992: Anat Achiron; E Pras; Ronit Gilad; I Ziv; M Mandel; C R Gordon; S Noy; Ida Sarova-Pinhas; Eldad Melamed
Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis.
Archives of neurology 1992;49(12):1233-6.
1992: Anat Achiron; Ilan Ziv; Ruth Djaldetti; H Goldberg; A Kuritzky; Eldad Melamed
Aphasia in multiple sclerosis: clinical and radiologic correlations.
Neurology 1992;42(11):2195-7.
1992: R Djaldetti; I Ziv; A Achiron; Eldad Melamed
Parkinson's disease in a patient with mitochondrial myopathy: is there a causative relationship?
Movement disorders : official journal of the Movement Disorder Society 1992;7(4):382-3.
1992: A Kuritzky; Y Zoldan; Eldad Melamed
Selegeline, a MAO B inhibitor, is not effective in the prophylaxis of migraine without aura--an open study.
Headache 1992;32(8):416.
1992: I Ziv; G Fleminger; Ruth Djaldetti; Anat Achiron; Eldad Melamed; M Sokolovsky
Increased plasma endothelin-1 in acute ischemic stroke.
Stroke; a journal of cerebral circulation 1992;23(7):1014-6.
1992: Eldad Melamed
Biochemical and functional differences between dopamine formed from endogenous tyrosine and exogenous L-dopa in nigrostriatal dopaminergic neurons.
Neurochemistry international 1992;20 Suppl():115S-117S.
1991: Eldad Melamed; A Achiron; A Shapira; S Davidovicz
Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome?
Clinical neuropharmacology 1991;14(3):273-8.
1990: S D Michowiz; Eldad Melamed; E Pikarsky; Z H Rappaport
Effect of ischemia induced by middle cerebral artery occlusion on superoxide dismutase activity in rat brain.
Stroke; a journal of cerebral circulation 1990;21(11):1613-7.
1990: Eldad Melamed; J Rosenthal; Moussa B H Youdim
Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Journal of neurochemistry 1990;55(4):1427-31.
1990: A Achiron; I Ziv; Eldad Melamed
[Aluminium and Alzheimer's disease].
Harefuah 1990;118(11):674-5.
1990: A Achiron; Y Zoldan; Eldad Melamed
Tardive dyskinesia induced by sulpiride.
Clinical neuropharmacology 1990;13(3):248-52.
1990: Anat Achiron; M Gornish; Eldad Melamed
Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.
Stroke; a journal of cerebral circulation 1990;21(5):817-9.
1990: N Arber; H Shirin; R Fadila; Eldad Melamed; J Pinkhas; Y Sidi
Pseudotumor cerebri associated with leuprorelin acetate.
Lancet 1990;335(8690):668.
1990: A Achiron; Eldad Melamed
Tardive eating dystonia.
Movement disorders : official journal of the Movement Disorder Society 1990;5(4):331-3.
1990: Eldad Melamed
Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
Advances in neurology 1990;53():61-6.
1989: A Achiron; M Mendel; G Rechavi; B Ramot; Eldad Melamed
Changes in T-cell subpopulations in multiple sclerosis.
Annals of neurology 1989;26(2):291-2.
1989: N Gadoth; D Abramovitch; Eldad Melamed
The regional cerebral blood flow in familial dysautonomia.
Brain & development 1989;11(3):179-82.
1988: Shaul Feldman; N Conforti; Eldad Melamed
Hypothalamic norepinephrine mediates limbic effects on adrenocortical secretion.
Brain research bulletin 1988;21(4):587-90.
1988: Tali Siegal; Eldad Melamed; U Sandbank; R Catane
Early and delayed neurotoxicity of mitoxantrone and doxorubicin following subarachnoid injection.
Journal of neuro-oncology 1988;6(2):135-40.
1988: Eldad Melamed
Brain grafting may reverse loss of responsiveness to levodopa therapy in Parkinson's disease.
Clinical neuropharmacology 1988;11(1):77-82.
1988: Shaul Feldman; N Conforti; Eldad Melamed
Involvement of ventral noradrenergic bundle in corticosterone secretion following neural stimuli.
Neuropharmacology 1988;27(2):129-33.
1988: Eldad Melamed
Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
The Mount Sinai journal of medicine, New York 1988;55(1):35-42.
1987: Eldad Melamed; D Soffer; J Rosenthal; E Pikarsky; A Reches
Effect of intrastriatal and intranigral administration of synthetic neuromelanin on the dopaminergic neurotoxicity of MPTP in rodents.
Neuroscience letters 1987;83(1-2):41-6.
1987: E Pikarsky; Eldad Melamed; J Rosenthal; A Uzzan; S D Michowiz
The neurotoxin MPTP does not affect striatal superoxide dismutase activity in mice.
Neuroscience letters 1987;82(3):327-31.
1987: Israel Steiner; R Shahin; Eldad Melamed
Acute "upside down" reversal of vision in transient vertebrobasilar ischemia.
Neurology 1987;37(10):1685-6.
1987: D Gottlieb; B Mildworf; D Rubinger; Eldad Melamed
The regional cerebral blood flow in patients under chronic hemodialytic treatment.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1987;7(5):659-61.
1987: Eldad Melamed; B Mildworf; T Sharav; L Belenky; E Wertman
Regional cerebral blood flow in Down's syndrome.
Annals of neurology 1987;22(2):275-8.
1987: D Kidron; Eldad Melamed
Forms of dystonia in patients with Parkinson's disease.
Neurology 1987;37(6):1009-11.
1987: R H Fishman; A B Pleet; Eldad Melamed; O Abramsky
Regional brain superoxide dismutase activity is altered differently by heat in warm and cool mice.
Brain research 1987;410(2):343-6.
1987: S Feldman; N Conforti; Eldad Melamed
Paraventricular nucleus serotonin mediates neurally stimulated adrenocortical secretion.
Brain research bulletin 1987;18(2):165-8.
1987: Eldad Melamed; M Globus; J Rosenthal; A Uzzan
Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
Advances in neurology 1987;45():507-10.
1987: D Kidron; I Steiner; Eldad Melamed
Late-onset progressive radiculomyelopathy in patients with cervical athetoid-dystonic cerebral palsy.
European neurology 1987;27(3):164-6.
1986: Eldad Melamed; E Pikarski; A Goldberg; J Rosenthal; A Uzzan; N Conforti
Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in mice.
Brain research 1986;399(1):178-80.
1986: D Soffer; Eldad Melamed; Y Assaf; S Cotev
Hemispheric brain damage in unilateral status epilepticus.
Annals of neurology 1986;20(6):737-40.
1986: Eldad Melamed; M Globus; B Mildworf
Regional cerebral blood flow in patients with Parkinson's disease under chronic levodopa therapy: measurements during "on" and "off" response fluctuations.
Journal of neurology, neurosurgery, and psychiatry 1986;49(11):1301-4.
1986: D Gottlieb; S Fields; V Bitton; M Gomori; D Kidron; Eldad Melamed
[Clinical-roentgenological study of degenerative spinocerebellar diseases].
Harefuah 1986;111(7-8):165-7.
1986: Eldad Melamed; G Martinovits; E Pikarsky; J Rosenthal; A Uzzan
Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice.
European journal of pharmacology 1986;128(3):255-7.
1986: G Martinovits; Eldad Melamed; O Cohen; J Rosenthal; A Uzzan
Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP).
Neuroscience letters 1986;69(2):192-7.
1986: S Feldman; N Conforti; Eldad Melamed
Noradrenergic mediation of adrenocortical responses following cortical stimulation in the rat.
Israel journal of medical sciences 1986;22(7-8):591-3.
1986: B Mildworf; M Globus; Eldad Melamed
[Measurement of cognitive functions in Parkinson's disease].
Harefuah 1986;110(10):501-3.
1986: Eldad Melamed; Y Frucht; J Vidauri; A Uzzan; J Rosenthal
Effect of postnatal light deprivation on the ontogenesis of dopamine neurons in rat retina.
Brain research 1986;391(2):280-4.
1986: Eldad Melamed
Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease.
Archives of neurology 1986;43(4):402-5.
1986: S Feldman; N Conforti; Eldad Melamed
Norepinephrine depletion in the paraventricular nucleus inhibits the adrenocortical responses to neural stimuli.
Neuroscience letters 1986;64(2):191-5.
1986: M J Baum; Eldad Melamed; M Globus
Dissociation of the effects of castration and testosterone replacement on sexual behavior and neural metabolism of dopamine in the male rat.
Brain research bulletin 1986;16(2):145-8.
1986: Eldad Melamed; V Bitton; O Zelig
Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.
Neurology 1986;36(1):100-3.
1986: Eldad Melamed; V Bitton; O Zelig
Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy.
Clinical neuropharmacology 1986;9(2):182-8.
1985: Eldad Melamed; Moussa B H Youdim; J Rosenthal; I Spanier; A Uzzan; M Globus
In vivo effect of MPTP on monoamine oxidase activity in mouse striatum.
Brain research 1985;359(1-2):360-3.
1985: Eldad Melamed; Moussa B H Youdim
Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.
British journal of pharmacology 1985;86(3):529-31.
1985: Eldad Melamed; J Rosenthal; O Cohen; M Globus; A Uzzan
Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
European journal of pharmacology 1985;116(1-2):179-81.
1985: Eldad Melamed; J Rosenthal; M Globus; O Cohen; A Uzzan
Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA.
Brain research 1985;342(2):401-4.
1985: Eldad Melamed; J Rosenthal; O Cohen; A Uzzan; M Globus
Amphetamine, but not reserpine, protects mice against dopaminergic neurotoxicity of MPTP.
Neuropharmacology 1985;24(9):923-5.
1985: Eldad Melamed; J Rosenthal; M Globus; O Cohen; Y Frucht; A Uzzan
Mesolimbic dopaminergic neurons are not spared by MPTP neurotoxicity in mice.
European journal of pharmacology 1985;114(1):97-100.
1985: M Globus; Eldad Melamed
Progressive age-related decrease in regional cerebral blood flow in healthy subjects.
Israel journal of medical sciences 1985;21(8):662-5.
1985: M Globus; B Mildworf; Eldad Melamed
Cerebral blood flow and cognitive impairment in Parkinson's disease.
Neurology 1985;35(8):1135-9.
1985: J Yanai; P Y Sze; C Iser; Eldad Melamed
Studies on brain monoamine neurotransmitters in mice after prenatal exposure to barbiturate.
Pharmacology, biochemistry, and behavior 1985;23(2):215-9.
1985: V Barash; M Globus; Eldad Melamed; J Weidenfeld
Effect of L-DOPA on glucose oxidation and incorporation into glycogen in discrete brain regions of the rat.
Brain research 1985;335(2):347-9.
1985: Eldad Melamed; F Hefti
Altered pharmacokinetics of L-dopa metabolism.
Neurology 1985;35(6):939-41.
1985: I Steiner; J M Gomori; Eldad Melamed
Progressive brain atrophy during normal aging in man: a quantitative computerized tomography study.
Israel journal of medical sciences 1985;21(3):279-82.
1985: H R Freund; M Muggia-Sullam; J Peiser; Eldad Melamed
Brain neurotransmitter profile is deranged during sepsis and septic encephalopathy in the rat.
The Journal of surgical research 1985;38(3):267-71.
1985: I Steiner; Z Argov; J M Gomori; D Gottlieb; Eldad Melamed
Immediate spasticity with acute hemiplegia is a sign of basal ganglia hemorrhage.
Acta neurologica Scandinavica 1985;71(2):168-70.
1985: I Steiner; J M Gomori; Eldad Melamed
Features of brain atrophy in Parkinson's disease. A CT scan study.
Neuroradiology 1985;27(2):158-60.
1985: T Siegal; B Mildworf; D Stein; Eldad Melamed
Leptomeningeal metastases: reduction in regional cerebral blood flow and cognitive impairment.
Annals of neurology 1985;17(1):100-2.
1985: F Hefti; Albert Enz; Eldad Melamed
Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs.
Neuropharmacology 1985;24(1):19-23.
1984: Eldad Melamed; F Hefti; V Bitton; M Globus
Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
Neurology 1984;34(12):1566-70.
1984: I Steiner; Eldad Melamed
Conjugate eye deviation after acute hemispheric stroke: delayed recovery after previous contralateral frontal lobe damage.
Annals of neurology 1984;16(4):509-11.
1984: S Feldman; Eldad Melamed; N Conforti; J Weidenfeld
Effect of central serotonin depletion on adrenocortical responses to neural stimuli.
Experimental neurology 1984;85(3):661-6.
1984: Eldad Melamed; Y Frucht; M Lemor; A Uzzan; Y Rosenthal
Dopamine turnover in rat retina: a 24-hour light-dependent rhythm.
Brain research 1984;305(1):148-51.
1984: J R Berger; William A Sheremata; Eldad Melamed
Paroxysmal dystonia as the initial manifestation of multiple sclerosis.
Archives of neurology 1984;41(7):747-50.
1984: E Wertman; Eldad Melamed
[Senile dementia--recent developments].
Harefuah 1984;107(1-2):39-42.
1984: Y Frucht; Eldad Melamed
The dopaminergic amacrine system and its response to light stimulation in rats with inherited retinal dystrophy.
Experimental eye research 1984;38(4):391-8.
1984: I Steiner; J M Gomori; Eldad Melamed
The prognostic value of the CT scan in conservatively treated patients with intracerebral hematoma.
Stroke; a journal of cerebral circulation 1984;15(2):279-82.
1984: I Steiner; I Polacheck; Eldad Melamed
Dementia and myoclonus in a case of cryptococcal encephalitis.
Archives of neurology 1984;41(2):216-7.
1984: J M Gomori; I Steiner; Eldad Melamed; G Cooper
The assessment of changes in brain volume using combined linear measurements. A CT-scan study.
Neuroradiology 1984;26(1):21-4.
1984: M Globus; G Cooper; Eldad Melamed
Reduction in regional cerebral blood flow during normal aging is not limited to elderly subjects.
Monographs in neural sciences 1984;11():139-43.
1984: Eldad Melamed; F Hefti
Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons.
Advances in neurology 1984;40():149-57.
1984: S Feldman; R A Siegel; J Weidenfeld; N Conforti; Eldad Melamed
Adrenocortical responses to ether stress and neural stimuli in rats following the injection of 6-hydroxydopamine into the medial forebrain bundle.
Experimental neurology 1984;83(1):215-20.
1984: V Bitton; Eldad Melamed
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
The Journal of clinical psychiatry 1984;45(1):28-30.
1984: S Feldman; Eldad Melamed; N Conforti; J Weidenfeld
Inhibition in corticotrophin and corticosterone secretion following photic stimulation in rats with 6-hydroxydopamine injection into the medial forebrain bundle.
Journal of neuroscience research 1984;12(1):87-92.
1983: I Steiner; Eldad Melamed
[Steroid treatment in brain edema].
Harefuah 1983;105(12):432-4.
1983: I Steiner; Eldad Melamed
Folic acid and the nervous system.
Neurology 1983;33(12):1634.
1983: M Globus; Eldad Melamed; A Keren; D Tzivoni; C Granot; S Lavy; S Stern
Effect of exercise on cerebral circulation.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1983;3(3):287-90.
1983: R A Siegel; J Weidenfeld; M Chen; S Feldman; Eldad Melamed; I Chowers
Hippocampal cell nuclear binding of corticosterone following 5,7-dihydroxytryptamine.
Molecular and cellular endocrinology 1983;31(2-3):253-9.
1983: Eldad Melamed; M Globus; E Friedlender; J Rosenthal
Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections.
Neurology 1983;33(7):950-3.
1983: S Feldman; R A Siegel; J Weidenfeld; N Conforti; Eldad Melamed
Adrenocortical secretion following photic stimulation mediated by medial forebrain bundle catecholaminergic fibers.
Israel journal of medical sciences 1983;19(7):662-4.
1983: Eldad Melamed; R Durst; Y Frucht; M Globus
Differential effect of acute and chronic haloperidol administration on dopamine turnover in rat nigrostriatal and retinal dopaminergic neurons.
European journal of pharmacology 1983;89(3-4):279-82.
1983: S Feldman; R A Siegel; J Weidenfeld; N Conforti; Eldad Melamed
Role of medial forebrain bundle catecholaminergic fibers in the modulation of glucocorticoid negative feedback effects.
Brain research 1983;260(2):297-300.
1983: M Globus; Eldad Melamed; N Conforti
Effect of decortication on striatal dopamine turnover.
Clinical neuropharmacology 1983;6(3):247-52.
1983: M Globus; Eldad Melamed
Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum.
Progress in neuro-psychopharmacology & biological psychiatry 1983;7(2-3):211-5.
1982: M Globus; Eldad Melamed; A Keren; D Tzivoni; S Stern
[Cerebral blood flow in hypertension].
Harefuah 1982;103(10):240-2.
1982: Eldad Melamed
[Regional cerebral blood flow in the aging human brain and in Alzheimer's dementia and Parkinson's disease].
Harefuah 1982;103(10):234-6.
1982: Y Frucht; J Vidauri; Eldad Melamed
Light activation of dopaminergic neurons in rat retina is mediated through photoreceptors.
Brain research 1982;249(1):153-6.
1982: W Lichtensteiger; F Hefti; D Felix; T Huwyler; Eldad Melamed; M Schlumpf
Stimulation of nigrostriatal dopamine neurones by nicotine.
Neuropharmacology 1982;21(10):963-8.
1982: Eldad Melamed; F Hefti; E D Bird
Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions.
Neurology 1982;32(6):640-4.
1982: John H Growdon; Eldad Melamed; M Logue; F Hefti; R J Wurtman
Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease.
Life sciences 1982;30(10):827-32.
1982: Eldad Melamed; F Hefti; R J Wurtman
Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model.
Israel journal of medical sciences 1982;18(1):159-63.
1981: F Hefti; Eldad Melamed
Dopamine release in rat striatum after administration of L-dope as studied with in vivo electrochemistry.
Brain research 1981;225(2):333-46.
1981: Eldad Melamed; F Hefti; D J Pettibone; J Liebman; R J Wurtman
Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism.
Neurology 1981;31(6):651-5.
1981: F Hefti; Eldad Melamed; R J Wurtman
The site of dopamine formation in rat striatum after L-dopa administration.
The Journal of pharmacology and experimental therapeutics 1981;217(1):189-97.
1980: Eldad Melamed; F Hefti; R J Wurtman
Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
Annals of neurology 1980;8(6):558-63.
1980: R J Wurtman; F Hefti; Eldad Melamed
Precursor control of neurotransmitter synthesis.
Pharmacological reviews 1980;32(4):315-35.
1980: Eldad Melamed; F Hefti; R J Wurtman
Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries.
Brain research 1980;198(1):244-8.
1980: F Hefti; Eldad Melamed; R J Wurtman
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.
Brain research 1980;195(1):123-37.
1980: Eldad Melamed; F Hefti; R J Wurtman
Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(7):4305-9.
1980: Eldad Melamed; F Hefti; R J Wurtman
L-3,4-Dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities in rat striatum: effect of selective destruction of dopaminergic or serotoninergic input.
Journal of neurochemistry 1980;34(6):1753-6.
1980: Eldad Melamed; F Hefti; R J Wurtman
Diminished decarboxylation of L-DOPA in rat striatum after intrastriatal injections of kainic acid.
Neuropharmacology 1980;19(4):409-11.
1980: Eldad Melamed; F Hefti; J Liebman; A J Schlosberg; R J Wurtman
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Nature 1980;283(5749):772-4.
1980: F Hefti; Eldad Melamed; Barbara J Sahakian; R J Wurtman
Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA.
Pharmacology, biochemistry, and behavior 1980;12(2):185-8.
1980: S Lavy; S Stern; Eldad Melamed; G Cooper; A Keren; P Levy
Effect of chronic atrial fibrillation on regional cerebral blood flow.
Stroke; a journal of cerebral circulation 1980;11(1):35-8.
1980: Eldad Melamed; S Lavy; S Bentin; G Cooper; Y Rinot
Reduction in regional cerebral blood flow during normal aging in man.
Stroke; a journal of cerebral circulation 1980;11(1):31-5.
1980: Eldad Melamed; B Glaeser; John H Growdon; R J Wurtman
Plasma tyrosine in normal humans: effects of oral tyrosine and protein-containing meals.
Journal of neural transmission 1980;47(4):299-306.
1980: F Hefti; Eldad Melamed; R J Wurtman
The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model.
Journal of neural transmission. Supplementum 1980;(16):95-101.
1979: M A Moskowitz; J F Reinhard; J Romero; Eldad Melamed; D J Pettibone
Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine?
Lancet 1979;2(8148):883-5.
1979: S Lavy; Eldad Melamed; G Cooper; S Bentin; Y Rinot
Regional cerebral blood flow in patients with Parkinson's disease.
Archives of neurology 1979;36(6):344-8.
1979: Eldad Melamed
Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease.
Archives of neurology 1979;36(5):308-10.
1979: J R Berger; M Globus; Eldad Melamed
Acute transitory cerebellar dysfunction associated with piperazine adipate.
Archives of neurology 1979;36(3):180-1.
1979: Z Argov; Eldad Melamed; S Katz
Hyperparathyroidism presenting with unusual neurological features.
European neurology 1979;18(5):338-40.
1979: Eldad Melamed; S Lavy
Effect of papaverine on regional cerebral blood flow of the contralateral hemisphere in patients with acute cerebral infarction.
Applied neurophysiology 1979;42(4):217-23.
1979: Eldad Melamed; B Larsen
Cortical activation pattern during saccadic eye movements in humans: localization by focal cerebral blood flow increases.
Annals of neurology 1979;5(1):79-88.
1978: Eldad Melamed; I Korn-Lubetzki; A Reches; F Siew
Hemiballismus: detection of focal hemorrhage in subthalamic nucleus by CT scan.
Annals of neurology 1978;4(6):582.
1978: S Lavy; Eldad Melamed; S Bentin; G Cooper; Y Rinot
Bihemispheric decreases of regional cerebral blood flow in dementia: correlation with age-matched normal controls.
Annals of neurology 1978;4(5):445-50.
1978: Eldad Melamed; S Lavy; G Cooper; S Bentin
Regional cerebral blood flow in parkinsonism. Measurement before and after levodopa.
Journal of the neurological sciences 1978;38(3):391-7.
1978: Eldad Melamed; S Lavy; F Siew; S Bentin; G Cooper
Correlation between regional cerebral blood flow and brain atrophy in dementia. Combined study with 133Xenon inhalation and computerised tomography.
Journal of neurology, neurosurgery, and psychiatry 1978;41(10):894-9.
1978: P Yarnell; Eldad Melamed; R Silverberg
Global hemianaesthesia: a parietal perceptual distortion suggesting non-organic illness.
Journal of neurology, neurosurgery, and psychiatry 1978;41(9):843-6.
1978: Eldad Melamed; M Luhar; D Atlas
Histochemical labeling of beta-adrenergic receptors in the mouse central nervous system by 9-amino-acridin propranolol.
Neurology 1978;28(8):850-3.
1978: D Atlas; Eldad Melamed
Direct mapping of beta-adrenergic receptors in the rat central nervous system by a novel fluorescent beta-blocker.
Brain research 1978;150(2):377-85.
1977: Eldad Melamed; M Lahav; D Atlas
beta-Adrenergic receptors in rat cerebral cortex: histochemical localization by a fluorescent beta-blocker.
Brain research 1977;128(2):379-84.
1977: Eldad Melamed; S Lavy
Parkinsonism associated with chronic inhalation of carbon tetrachloride.
Lancet 1977;1(8019):1015.
1977: Eldad Melamed; D Atlas; M Lahav
Direct evidence for absence of beta-adrenergic receptors in rat cerebral vessels histochemical study with a fluorescent beta-blocker.
Stroke; a journal of cerebral circulation 1977;8(2):261-3.
1977: S Lavy; Eldad Melamed; Z Portnoy; A Carmon
Regional cerebral blood flow in the epileptic brain during the seizure-free interval.
Acta neurologica Scandinavica. Supplementum 1977;64():232-3.
1977: Eldad Melamed; B Larsen
Regional cerebral blood flow during voluntary conjugate eye movements in man.
Acta neurologica Scandinavica. Supplementum 1977;64():530-1.
1977: N A Lassen; P E Roland; B Larsen; Eldad Melamed; K Soh
Mapping of human cerebral functions: a study of the regional cerebral blood flow pattern during rest, its reproducibility and the activations seen during basic sensory and motor functions.
Acta neurologica Scandinavica. Supplementum 1977;64():262-3, 274-5.
1977: S Lavy; Eldad Melamed; Z Portnoy
Cerebral blood flow response in non affected hemisphere of patients with acute cerebral infarction.
Acta neurologica Scandinavica. Supplementum 1977;64():246-7.
1976: Eldad Melamed; M Lahav; D Atlas
Histochemical evidence for beta-adrenergic receptors in the rat spinal cord.
Brain research 1976;116(3):511-5.
1976: Eldad Melamed
Reactive hyperglycaemia in patients with acute stroke.
Journal of the neurological sciences 1976;29(2-4):267-75.
1976: Eldad Melamed; A Reches
Internal carotid arterial occlusion simulating extracerebral hematoma: relation to diagnosis of stroke.
Journal of the American Geriatrics Society 1976;24(7):317-22.
1976: Eldad Melamed; M Lahav; D Atlas
Direct localisation of beta-adrenoceptor sites in rat cerebellum by a new fluorescent analogue of propranolol.
Nature 1976;261(5559):420-2.
1976: S Lavy; Eldad Melamed; Z Portnoy; A Carmon
Interictal regional cerebral blood flow in patients with partial seizures.
Neurology 1976;26(5):418-22.
1976: Eldad Melamed; E A Rachmilewitz; A Reches; S Lavy
Aseptic cavernous sinus thrombosis after internal carotid arterial occlusion in polycythaemia vera.
Journal of neurology, neurosurgery, and psychiatry 1976;39(4):320-4.
1975: Eldad Melamed; S Lavy; Z Portnoy
Regional cerebral blood flow response to hypocapnia in the contralateral hemisphere of patients with acute cerebral infarction.
Stroke; a journal of cerebral circulation 1975;6(5):503-8.
1975: Eldad Melamed; S Lavy; Z Portnoy; S Sadan; A Carmon
Correlation between regional cerebral blood flow and EEG frequency in the contralateral hemisphere in acute cerebral infarction.
Journal of the neurological sciences 1975;26(1):21-7.
1975: Eldad Melamed; A Reches; C Hershko
Reversible central nervous system dysfunction in folate deficiency.
Journal of the neurological sciences 1975;25(1):93-8.
1975: S Lavy; Eldad Melamed; Z Portnoy
The effect of cerebral infarction on the regional cerebral blood flow of the contralateral hemisphere.
Stroke; a journal of cerebral circulation 1975;6(2):160-3.
1975: F A Abraham; Eldad Melamed; S Lavy
Prognostic value of visual evoked potentials in occipital blindness following basilar artery occlusion.
Applied neurophysiology 1975;38(2):126-35.
1975: Eldad Melamed; C Cohen; D Soffer; S Lavy
Central nervous system complication in a patient with chronic gaucher's disease.
European neurology 1975;13(2):167-75.
1975: Eldad Melamed; S Lavy; A Reches; A Sahar
Chronic subdural hematoma simulating transient cerebral ischemic attacks. Case report.
Journal of neurosurgery 1975;42(1):101-3.
1974: S Lavy; I Yaar; Eldad Melamed; S Stern
The effect of acute stroke on cardiac functions as observed in an intensive stroke care unit.
Stroke; a journal of cerebral circulation 1974;5(6):775-80.
1974: Eldad Melamed; F A Abraham; S Lavy
Cortical blindness as a manifestation of basilar artery occlusion.
European neurology 1974;11(1):22-9.
1973: S Lavy; Eldad Melamed; E Cahane; A Carmon
Hypertension and diabetes as risk factors in stroke patients.
Stroke; a journal of cerebral circulation 1973;4(5):751-9.
1973: Eldad Melamed; E Cahane; A Carmon; S Lavy
Stroke in Jerusalem district 1960 through 1967: an epidemiological study.
Stroke; a journal of cerebral circulation 1973;4(3):465-71.